Announcements Trials
Browse Landscape

Phase

Phase 4 3Phase 3 3Phase NA 1Phase 2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 3

Conditions

Pituitary Neoplasms 2Pituitary ACTH Hypersecretion 1Adenoma 1ACTH-Secreting Pituitary Adenoma 1

Interventions

Everolimus 8lanreotide 7Octreotide 7lutetium Lu 177 dotatate 6pasireotide 5Thyrotropin Alfa 5Mitotane 4Etoposide 4Doxorubicin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4amino-acid, glucose, and electrolyte solution 3Mifepristone 3Filgrastim 3Corlux 3Cisplatin 3Chemotherapy, Adjuvant 3Capecitabine 3Cabergoline 3vandetanib 2telotristat ethyl 2surufatinib 2ribociclib 2fluorodopa F 18 2cabozantinib 2Temozolomide 2Receptor-Like Protein Tyrosine Phosphatases, Class 2 2Lutetium-177 2Lutetium 2Leucovorin 2Iodine-131 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Cabergoline × Endocrine × Clear all
NCT02288962 2025-06-08

Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas

St. Olavs Hospital

Phase 3 Active not recruiting
60 enrolled
Endocrine

Adenoma, Pituitary Neoplasms

NCT03271918 2017-09-07

Cabergoline in Nonfunctioning Pituitary Adenomas

University of Sao Paulo General Hospital

Phase 3 Completed
140 enrolled
Endocrine

Pituitary Neoplasms

NCT00889525 2009-04-29

Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor

Seth Gordhandas Sunderdas Medical College

Phase 3 Completed
Endocrine

Pituitary ACTH Hypersecretion, ACTH-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡